Relationship between plasma high-mobility group box-1 levels and clinical outcomes of ischemic stroke

被引：37

作者：

Huang, Ju-Ming ^{[1
]}

Hu, Jin ^{[1
]}

Chen, Ning ^{[1
]}

Hu, Min-Lei ^{[1
]}

机构：

[1] First Hosp Jia Xing, Dept Neurol, Jiaxing 314001, Peoples R China

来源：

JOURNAL OF CRITICAL CARE | 2013年 / 28卷 / 05期

关键词：

Ischemic stroke; High mobility group box-1; Outcome; CHROMATIN PROTEIN HMGB1; GLYCATION END-PRODUCTS; SUBARACHNOID HEMORRHAGE; BRAIN; ACTIVATION; CYTOKINE; MEDIATOR; RECEPTOR; RELEASE; CELLS;

D O I：

10.1016/j.jcrc.2012.10.003

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

Purpose: High-mobility group box-1 (HMGB1) is regarded as a central mediator of inflammation and involved in many inflammatory diseases. This study aimed to investigate impact of plasma HMGB1 level on 1-year clinical outcomes of ischemic stroke. Methods: Plasma HMGB1 levels of 338 patients were quantified by enzyme-linked immunosorbent assay. The end points were mortality and unfavorable outcome (modified Rankin Scale score>2) after 1 year. Results: Plasma HMGB1 level emerged as an independent predictor of 1-year clinical outcomes. Its prognostic value was similar to National Institutes of Health Stroke Scale score's. It improved prognostic value of National Institutes of Health Stroke Scale score. Conclusion: Plasma HMGB1 level represents a novel biomarker for predicting 1-year clinical outcomes of ischemic stroke. (C) 2013 Elsevier Inc. All rights reserved.

引用

页码：792 / 797

页数：6

共 32 条

[1] Cutting edge: HMG-1 as a mediator of acute lung inflammation
Abraham, E
Arcaroli, J
Carmody, A
Wang, HC
Tracey, KJ
[J]. JOURNAL OF IMMUNOLOGY, 2000, 165 (06) : 2950 - 2954
[2] HMGB-1, a DNA-binding protein with cytokine activity, induces brain TNF and IL-6 production, and mediates anorexia and taste aversion
Agnello, D
Wang, HC
Yang, H
Tracey, KJ
Ghezzi, P
[J]. CYTOKINE, 2002, 18 (04) : 231 - 236
[3] High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity
Bianchi, Marco E.
Manfredi, Angelo A.
[J]. IMMUNOLOGICAL REVIEWS, 2007, 220 : 35 - 46
[4] Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion
Bonaldi, T
Talamo, F
Scaffidi, P
Ferrera, D
Porto, A
Bachi, A
Rubartelli, A
Agresti, A
Bianchi, ME
[J]. EMBO JOURNAL, 2003, 22 (20) : 5551 - 5560
[5] Bustin M, 1999, MOL CELL BIOL, V19, P5237
[6] HMGB1: guiding immunity from within
Dumitriu, IE
Baruah, P
Manfredi, AA
Bianchi, ME
Rovere-Querini, P
[J]. TRENDS IN IMMUNOLOGY, 2005, 26 (07) : 381 - 387
[7] Elevated high-mobility group box 1 levels in patients with cerebral and myocardial ischemia
Goldstein, Richard S.
Gallowitsch-Puerta, Margot
Yang, LiHong
Rosas-Ballina, Mauricio
Huston, Jared M.
Czura, Christopher J.
Lee, David C.
Ward, Mae F.
Bruchfeld, Annette N.
Wang, Haichao
Lesser, Martin L.
Church, Adam L.
Litroff, Adam H.
Sama, Andrew E.
Tracey, Kevin J.
[J]. SHOCK, 2006, 25 (06): : 571 - 574
[8] Interleukin-33-cytokine of dual function or novel alarmin?
Haraldsen, Guttorm
Balogh, Johanna
Pollheimer, Jurgen
Sponheim, Jon
Kuchler, Axel M.
[J]. TRENDS IN IMMUNOLOGY, 2009, 30 (05) : 227 - 233
[9] Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-κB require the cytoplasmic domain of the receptor but different downstream signaling pathways
Huttunen, HJ
Fages, C
Rauvala, H
[J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (28) : 19919 - 19924
[10] Amphoterin as an extracellular regulator of cell motility: from discovery to disease
Huttunen, HJ
Rauvala, H
[J]. JOURNAL OF INTERNAL MEDICINE, 2004, 255 (03) : 351 - 366

← 1 2 3 4 →